Anti‐EGFR therapy vs placebo or usual care
Progression‐free survival · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in progression‐free survival ‐ first‐line studies compared with placebo or standard of care (low certainty).
1 finding from 1 review
- Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes onlyHR 0.94 [0.81, 1.1]2 studies · 894 participantsLow